(1R,2R)-1-Amino-2-(difluoromethyl)-N-((1-methylcyclopropyl)sulfonyl)cyclopropane-1-carboxamide hydrochloride is a chiral cyclopropane derivative featuring an amino group, a difluoromethyl group, and a (1-methylcyclopropyl)sulfonyl carboxamide moiety. It is a key synthetic intermediate in the production of novel antibacterial agents. This compound is a crucial building block in the synthesis of Gepotidacin (GSK2140944), a first-in-class triazaacenaphthylene bacterial topoisomerase inhibitor developed by GlaxoSmithKline. Gepotidacin targets bacterial DNA gyrase and topoisomerase IV through a unique mechanism, making it effective against drug-resistant pathogens, including multidrug-resistant *Neisseria gonorrhoeae* and *Staphylococcus aureus*. The specific stereochemistry and the difluoromethylcyclopropylamine core of this intermediate are essential for the biological activity of the final drug candidate. As a high-value pharmaceutical intermediate, its synthesis and supply are critical for the development and potential manufacturing of this promising antibiotic. It is handled under controlled conditions typical for advanced pharmaceutical intermediates.